Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2rgnull RIP-DTR mice engrafted with human islets
Chaoxing Yang,1 Matthias Loehn,2 Agata Jurczyk,1 Natalia Przewozniak,1 Linda Leehy,1 Pedro L Herrera,3 Leonard D Shultz,4 Dale L Greiner,1 David M Harlan,5 Rita Bortell1 1Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA, USA; 2Sa...
Guardado en:
Autores principales: | Yang C, Loehn M, Jurczyk A, Przewozniak N, Leehy L, Herrera PL, Shultz LD, Greiner DL, Harlan DM, Bortell R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a071891a076c4227b35229b952dc8abb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγnull mice treated with alogliptin
por: Jurczyk A, et al.
Publicado: (2013) -
Antibody repertoires in humanized NOD-scid-IL2Rγ(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse.
por: Gregory C Ippolito, et al.
Publicado: (2012) -
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013) -
Desmontando el desarrollo territorial rural (DTR) en América Latina
por: Gabriel Rodrigues Lopes
Publicado: (2015) -
The heterogeneity of reversion to normoglycemia according to prediabetes type is not explained by lifestyle factors
por: Carolina Giráldez-García, et al.
Publicado: (2021)